Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East

Table 2 Treatment and survival outcome

Variable	Total patients	Percentage
Initial treatment
Chemotherapy	100	50
Radiotherapy^a	13	6.5
Surgery alone	16	8
Chemotherapy + Radiotherapy	68	34
Rituximab alone	2	1
Refused / No show	1	0.5
Type of chemotherapy
ABVD^b	147	73.5
ABVD/ABV with COPP like	3	1.5
COPP^b	5	2.5
R-CHOP^c	11	5.5
Others^d	6	3
Number of initial chemo cycle
2 cycles ^a	31	15.5
3 cycles	11	5.5
4 cycles	64	32
6 cycles ^a	53	26.5
8 cycles	11	5.5
Response after initial treatment
CR	164	82
PR	11	5.5
PD^b	21	11.5
On treatment	1	0.5
Tissue confirmation at Rx failure
Type of first event	200	100
No event	124	62
Persistent disease	12	6
Progressive disease	21	10.5
Relapsed disease	36	18
Treatment related mortality	1	0.5
Death other causes	1	0.5
Unknown	5	2.5
Disease status at last visit
Alive in remission	176	88
Alive with disease	4	2
Alive unknown status	1	0.5
Lost to follow up	6	3
On treatment	2	1
Died of disease	8	4
Died of other cause^c	3	1.5
High grade transformation	11	5.5
HDC auto-SCT	29	14.5

Abbreviations: ABVD Adriamycin, bleomycin, vinblastin and dacarbazine, COPP/MOPP Cyclophosphamide / mechlorethamine, vincristine, procarbazine, prednisone, PR partial response
^a Rituximab × 4 before /or after radiotherapy in 2 patient, ^b Rituximab + ABVD in 9, Rituximab + COPP in 3, ^c Rituximab + CVP in 2, ^d Rituximab alone (3), rituximab + gemcitabine (1), dexamethasone, Ara-C, cisplatin (1), unknown at other institution (1). ^a 1 cycle in 2, 5 cycles in 4, ^b2 patients with no response (NR) or stable disease (SD) in this group, progressive disease (PD), complete remission (CR), complete remission unconfirmed (CRu), ^ctreatment related mortality in 2 (both with lung toxicity after R-ABVD, both in CR (1 for relapsed disease after radiation therapy). 1 patient with sickle cell related sever cardiomyopathy, died in CR

ISSN: 1471-2407